• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA grants IDE approval for Capillary Biomedical’s 7-day-wear infusion set

January 19, 2022 By Sean Whooley

Capillary BiomedicalCapillary Biomedical announced today that it received FDA investigational device exemption (IDE) for its SteadiFlow infusion technology.

Irvine, California-based Capillary Biomedical designed its new SteadiFlow seven-day-wear infusion set technology to significantly extend patient wear time to a week and maintain insulin stability.

The SteadiSet infusion set, powered by the SteadiFlow technology platform, features an integrated inserter designed for an easy, painless, hidden needle, one-handed insertion. In addition, the entire set includes materials to reduce preservative loss for improved insulin stability and reduced aggregate formation.

Capillary Biomedical designed its cannula to filter particles and aggregates before they are delivered to the tissue to ensure that any aggregates that form in the tubing are removed before reaching the tissue, reducing tissue inflammation and potentially improving infusion set reliability.

Garnering FDA IDE will lead to a new pivotal trial for the assessment of SteadiFlow. The non-randomized, prospective, single-arm trial will recruit at least 240 subjects between ages 18 and 80 years old with type 1 diabetes on insulin pump therapy across 15 sites. Each patient will undergo 12 one-week wear periods, according to a news release.

Jaeb Center for Health Research in Tampa, Florida, will serve as the contract research organization (CRO). The study will test Novolog and Humalog insulin.

“With this pivotal trial we are pleased to be taking a significant next step in the evolution of our SteadiFlow infusion set,” Capillary Biomedical CEO Paul Strasma said in the release. “Based on the strength of previous clinical data, we’re optimistic about the results of this forthcoming trial, and we’re excited to play a leadership role in what might be possible with insulin pump technology.”

Filed Under: Auto-injectors, Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: capillarybiomedical, FDA

IN CASE YOU MISSED IT

  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • FDA approves IND for Ananda Scientific’s PTSD treatment with liquid structure delivery tech
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
  • Jabil launches Qfinity reusable auto-injector

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS